

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method for the treatment of a disorder of the eye comprising:  
administering to a subject a therapeutically effective amount of a composition comprising a  
dsRNA between ~~15~~ 21 and ~~30~~ 23 nucleotides in length and a carrier, said dsRNA having a  
nucleotide sequence corresponding to mRNA of capable of modulating a target gene expressed  
in the eye in a therapeutically effective amount; said administering of the composition occurring  
outside the blood-retina barrier, and said composition inhibiting the target gene by RNA  
interference inside the eye.
2. (canceled)
3. (canceled)
4. (previously presented) The method of claim 1, wherein said disorder is related to  
angiogenesis and/or neovascularization.
5. (previously presented) The method of claim 1, wherein said disorder is related to the  
retinal pigment epithelium (RPE), neurosensory retina, choroid, and a combination thereof.
6. (previously presented) The method of claim 1, wherein said disorder is wet age-related  
macular degeneration (AMD) or diabetic retinopathy.
7. (canceled)
8. (canceled)
9. (currently amended) The method of claim 1, wherein said ~~compound~~ dsRNA is an  
inhibitor/~~antagonist~~ of ~~said~~ expression of the target gene.
10. (currently amended) The method of claim 9, wherein said ~~antagonist~~/inhibitor inhibits  
the expression of a the target gene involved in angiogenesis and/or neovascularization.
- 11.-15. (canceled)

16. (currently amended) The method of claim 1, wherein the dsRNA molecule ~~contains~~ comprises a terminal 3'-hydroxyl group.
- 17.-18. (canceled)
19. (currently amended) The method of claim 1, wherein said target gene ~~or a cDNA thereof~~ comprises SEQ ID NO: 3.
- 20.-91 (canceled)
92. (canceled) The method of claim 1, wherein the composition is designed as eye drops.
93. (canceled) The method of claim 1, wherein said dsRNA is between 20 and 25 nucleotides in length.
94. (new) The method of claim 1, further comprising preparing the dsRNA.
95. (new) The method of claim 1, further comprising diagnosing a subject with a disorder or a predisposition to a disorder of the eye.
96. (new) The method of claim 1, further comprising detecting a product of the target gene.
97. (new) The method of claim 1, further comprising isolating the target gene.
98. (new) The method of claim 1, wherein said administering is by systemic administration.